Published in Oncotarget on December 10, 2016
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet (2010) 4.46
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature (2006) 3.23
Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res (2006) 3.12
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol (2004) 2.59
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology (2001) 2.00
A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature (2002) 1.82
Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res (2005) 1.72
PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene (2006) 1.59
Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocr Relat Cancer (2013) 1.57
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer (2013) 1.57
Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell (2001) 1.52
The mediator coactivator complex: functional and physical roles in transcriptional regulation. J Cell Sci (2003) 1.41
Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis (2002) 1.27
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets (2009) 1.25
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog (2004) 1.13
Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci (2013) 1.12
Involvement of Mediator complex in malignancy. Biochim Biophys Acta (2013) 1.11
Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol (2011) 1.01
Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res (2005) 1.00
Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol (2013) 0.98
Mediator recruitment to heat shock genes requires dual Hsf1 activation domains and mediator tail subunits Med15 and Med16. J Biol Chem (2013) 0.95
A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res (2007) 0.95
Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway. Clin Exp Metastasis (2012) 0.92
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91
Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif. J Biol Chem (2011) 0.86
MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. Oncotarget (2015) 0.83
MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer. Int J Cancer (2013) 0.82
Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Mol Carcinog (2003) 0.81
In vitro and in vivo model systems used in prostate cancer research. J Biol Methods (2015) 0.81
Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget (2016) 0.80
Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology (2016) 0.82
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother (2015) 0.78
IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. Am J Pathol (2016) 0.76
Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget (2016) 0.75
Primary synovial cell sarcoma of the kidney: case report and review of the literature. Case Rep Oncol (2015) 0.75
Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine. PLoS One (2016) 0.75
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Mod Pathol (2014) 0.75
Patterns of stemness-associated markers in the development of castration-resistant prostate cancer. Prostate (2020) 0.75